Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Sarcoma 6 Solitary Fibrous Tumors 1 Sarcoma, Synovial 1 Sarcoma, Ewing 1 Recurrent High Grade Meningioma 1 Liposarcoma, Myxoid 1 Liposarcoma 1 Histiocytoma, Malignant Fibrous 1 Hemangioendothelioma 1 Chondrosarcoma, Mesenchymal 1

Interventions

Doxorubicin 7 pembrolizumab 5 Radiotherapy 5 Specimen Handling 4 Radiation 4 Magnetic Resonance Spectroscopy 4 palbociclib 3 eribulin 3 Ifosfamide 3 Biopsy 3 pazopanib 2 brigimadlin 2 abemaciclib 2 Immunoglobulin G 2 zimberelimab 1 toripalimab 1 talimogene laherparepvec 1 silmitasertib 1 selinexor 1 ribociclib 1 peposertib 1 pemigatinib 1 olaratumab 1 olaparib 1 mirdametinib 1 liposomal doxorubicin 1 lenvatinib 1 enzalutamide 1 durvalumab 1 cemiplimab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Liposarcoma × Trabectedin × 1 year × Clear all

NCT04794127 2026-02-18

TRABEPIO

Mario Negri Institute for Pharmacological Research

Phase 2 Completed

Liposarcoma, Liposarcoma, Myxoid

Data powered by HemOnc (CC BY 4.0) Colophon ⚡